RNS Number : 1416Z
Spectral MD Holdings, Ltd.
12 September 2022
 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Change of Interim Results Date

Investor Presentation

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that it will now release its interim results for the six months ended 30 June 2022 on Tuesday 20 September 2022.

 

Investor presentation

 

Wensheng Fan, Chief Executive Officer, and Nils Windler, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on Tuesday 20 September 2022 at 4.30 pm BST.

 

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am BST the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Spectral MD here.

 

Investors who already follow Spectral MD on the Investor Meet Company platform will automatically be invited.

 

For further information please contact:

 

Spectral MD Holdings, Ltd.

investors.spectralmd.com

Wensheng Fan, Chief Executive Officer

via Walbrook PR

Nils Windler, Chief Financial Officer

 

 

 

SP Angel Corporate Finance LLP (NOMAD and Joint Broker)

Tel: +44 (0)20 3470 0470

Stuart Gledhill/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Sales & Broking)

 

Stifel Nicolaus Europe Limited (Joint Broker)

Charles Hoare / Ben Maddison / Nick Harland /

Will Palmer-Brown

 

 

 

Tel: +44 (0)20 7710 7600

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Louis Ashe-Jepson

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

+44 (0)7407 804 654

 

About Spectral MD:                                                                                       

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORLTMBTMTABBPT